Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
Cancer Science · 2023
DOI: 10.1111/cas.15756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Tomofumi Watanabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Inamori Foundation, Japan Agency for Medical Research and Development, Japan Respiratory Foundation.
Abstract (Originalsprache)
Combination therapy with anti‐cytotoxic T lymphocyte‐associated protein 4 (CTLA‐4) and anti‐programmed death‐1 (PD‐1) monoclonal antibodies (mAbs) has dramatically improved the prognosis of patients with multiple types of cancer, including renal cell carcinoma (RCC). However, more than half of RCC patients fail to respond to this therapy. Regulatory T cells (Treg cells) are a subset of highly immunosuppressive CD4 + T cells that promote the immune escape of tumors by suppressing effector T cells in the tumor microenvironment (TME) through various mechanisms. CTLA‐4 is constitutively expressed in Treg cells and is regarded as a key molecule for Treg‐cell‐mediated immunosuppressive functions, suppressing antigen‐presenting cells by binding to CD80/CD86. Reducing Treg cells in the TME with an anti‐CTLA‐4 mAb with antibody‐dependent cellular cytotoxicity (ADCC) activity is considered an essential mechanism to achieve tumor regression. In contrast, we demonstrated that CTLA‐4 blockade without ADCC activity enhanced CD28 costimulatory signaling pathways in Treg cells and promoted Treg‐cell proliferation in mouse models. CTLA‐4 blockade also augmented CTLA‐4‐independent immunosuppressive functions, including cytokine production, leading to insufficient antitumor effects. Similar results were also observed in human peripheral blood lymphocytes and tumor‐infiltrating lymphocytes from patients with RCC. Our findings highlight the importance of Treg‐cell depletion to achieve tumor regression in response to CTLA‐4 blockade therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Urology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
ORCID-Profile: Yosuke Togashi
Förderung
- Inamori Foundation
- Japan Agency for Medical Research and Development
- Japan Respiratory Foundation
- Japan Science and Technology Agency
- Japan Society for the Promotion of Science
- Kato Memorial Bioscience Foundation
- MSD Life Science Foundation, Public Interest Incorporated Foundation
- Naito Foundation
Zitieren
APA
Watanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023). Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity. Cancer Science. https://doi.org/10.1111/cas.15756
Vancouver
Watanabe T, Ishino T, Ueda Y, Nagasaki J, Sadahira T, Dansako H, et al. Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity. Cancer Science. 2023. doi:10.1111/cas.15756
BibTeX
@article{Watanabe2023,
author = {Watanabe, Tomofumi and Ishino, Takamasa and Ueda, Youki and Nagasaki, Joji and Sadahira, Takuya and Dansako, Hiromichi and Araki, Motoo and Togashi, Yosuke},
title = {Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15756}
}
EUVIMED